Related references
Note: Only part of the references are listed.Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
Jeremy Chataway et al.
LANCET (2014)
Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial
Christian P. Kamm et al.
PLOS ONE (2014)
Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR--dependent mechanism
Ajaib S. Paintlia et al.
GLIA (2013)
Should people at low risk of cardiovascular disease take a statin?
John D. Abramson et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Inhibition of Interferon-beta Responses in Multiple Sclerosis Immune Cells Associated With High-Dose Statins
Xuan Feng et al.
ARCHIVES OF NEUROLOGY (2012)
Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
Christian Philipp Kamm et al.
JOURNAL OF NEUROLOGY (2012)
Statin therapy and multiple sclerosis disability in a population-based cohort
M. Mateo Paz Soldan et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Simvastatin improves final visual outcome in acute optic neuritis: a randomized study
Anna Tsakiri et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Randomized controlled trial of atorvastatin in clinically isolated syndrome The STAyCIS study
E. Waubant et al.
NEUROLOGY (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
Per Soelberg Sorensen et al.
LANCET NEUROLOGY (2011)
Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial
Mansoureh Togha et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy
Roberta Lanzillo et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis
R. A. Marrie et al.
NEUROLOGY (2010)
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a
R. A. Rudick et al.
NEUROLOGY (2009)
Statins: Mechanisms of neuroprotection
Peter J. van der Most et al.
PROGRESS IN NEUROBIOLOGY (2009)
The IFN-γ-induced transcriptional program of the CIITA gene is inhibited by statins
Sun J. Lee et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes
Xin Zhang et al.
JOURNAL OF IMMUNOLOGY (2008)
Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury
Hongtao Wu et al.
JOURNAL OF NEUROTRAUMA (2008)
Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis
J. Sellner et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis
G. Birnbaum et al.
NEUROLOGY (2008)
Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
Friedemann Paul et al.
PLOS ONE (2008)
Geranylgeranylation but Not GTP-Loading of Rho GTPases Determines T Cell Function
Sonia Waiczies et al.
SCIENCE SIGNALING (2008)
Simvastatin reduces the association of NMDA receptors to lipid rafts:: A cholesterol-mediated effect in neuroprotection
Jovita Ponce et al.
STROKE (2008)
Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis
Yinshan Zhao et al.
NEUROLOGY (2008)
Inflammatory biomarkers are associated with total brain volume - The Framingham Heart Study
A. L. Jefferson et al.
NEUROLOGY (2007)
Lipid raft microdomains and neurotransmitter signalling
John A. Allen et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Simvastatin regulates oligodendroglial process dynamics and survival
Veronique E. Miron et al.
GLIA (2007)
Statins induce differentiation and cell death in neurons and astroglia
Pia Maerz et al.
GLIA (2007)
Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases
Raffaella Ghittoni et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis
Xueyan Peng et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis
Igal Ifergan et al.
ANNALS OF NEUROLOGY (2006)
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity
O Stüve et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Simvastatin affects cell motility and actin cytoskeleton distribution of microglia
HF Kuipers et al.
GLIA (2006)
Atorvastatin induces T cell anergy via phosphorylation of ERK1
S Waiczies et al.
JOURNAL OF IMMUNOLOGY (2005)
Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis
MB Sättler et al.
EXPERIMENTAL NEUROLOGY (2005)
Differential effect of LFA703, pravastatin, and fluvastatin on. production of IL-18 and expression of ICAM-1 and CD40 in human monocytes
HK Takahashi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis
A Yilmaz et al.
ATHEROSCLEROSIS (2004)
Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases
BC Kieseier et al.
ARCHIVES OF NEUROLOGY (2004)
Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase protein kinase Akt and cardiovascular protection
S Wolfrum et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Oral simvastatin treatment in relapsing-remitting multiple sclerosis
T Vollmer et al.
LANCET (2004)
Therapeutic potential of lovastatin in multiple sclerosis
A Sena et al.
JOURNAL OF NEUROLOGY (2003)
Treating dyslipidemia with statins: The risk-benefit profile
LT Clark
AMERICAN HEART JOURNAL (2003)
Statin inhibits interferon-γ-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells
HK Chung et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2002)
Eight-year follow-up study of brain atrophy in patients with MS
E Fisher et al.
NEUROLOGY (2002)
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
S Youssef et al.
NATURE (2002)
Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis
R Stanislaus et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2001)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
G Weitz-Schmidt et al.
NATURE MEDICINE (2001)
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells
MT Montero et al.
ATHEROSCLEROSIS (2000)
Share Paper
